CPC A61K 9/1272 (2013.01) [A61K 9/1271 (2013.01); A61K 9/1277 (2013.01); A61K 47/6911 (2017.08); A61K 47/6913 (2017.08); C07K 16/2896 (2013.01); C12N 15/113 (2013.01); C12N 15/88 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C12N 2310/14 (2013.01); C12N 2310/531 (2013.01); Y02A 50/30 (2018.01)] | 12 Claims |
1. A hybridosome comprising a therapeutic agent encapsulated by a membrane of the hybridosome; wherein the membrane of the hybridosome comprises:
a. elements of a membrane of a first vesicle, wherein the elements of a membrane of the first vesicle comprise a fusogenic, ionizable cationic lipid, wherein said fusogenic, ionizable cationic lipid has at least one protonatable or deprotonatable group, such that the lipid is positively charged at a pH and neutral above the pH, and wherein said first vesicle has been produced in vitro such that the fusogenic, ionizable cationic lipid is present at a molar concentration of at least 30% of total lipid of the first vesicle; and
b. elements of a lipid bilayer of a second vesicle, wherein said second vesicle has been produced in vivo and is released into the extracellular environment.
|